ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP) $48.72 -1.24 (-2.48%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$48.39▼$50.2450-Day Range$48.72▼$65.4352-Week Range$36.54▼$65.89Volume133,033 shsAverage Volume129,564 shsMarket Capitalization$995.84 millionP/E Ratio93.69Dividend YieldN/APrice Target$71.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability ANI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.1% Upside$71.67 Price TargetShort InterestHealthy1.84% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$6.13 M Sold Last QuarterProj. Earnings Growth-11.73%From $3.58 to $3.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.61 out of 5 starsMedical Sector55th out of 957 stocksDrug Manufacturers - Specialty & Generic Industry2nd out of 11 stocks 3.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.67, ANI Pharmaceuticals has a forecasted upside of 47.1% from its current price of $48.72.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.84% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 11.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows6 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,127,760.00 in company stock.Percentage Held by Insiders28.50% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.78% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to decrease by -11.73% in the coming year, from $3.58 to $3.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 93.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.91.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 93.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.37.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ANI Pharmaceuticals Stock (NASDAQ:ANIP)ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesNovember 23, 2023 | stocknews.com3 Biotech Stocks to Buy to Help the Health of Your PortfolioNovember 22, 2023 | finance.yahoo.comANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceDecember 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 19, 2023 | finance.yahoo.comA Boring Biopharma Can Be a Good BetNovember 17, 2023 | finance.yahoo.comInsider Sell Alert: SVP, CHIEF HR OFFICER Krista Davis Sells Shares of ANI Pharmaceuticals IncNovember 11, 2023 | morningstar.comANI Pharmaceuticals Inc ANIPNovember 10, 2023 | finance.yahoo.comIs ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Stock Price Struggling As A Result Of Its Mixed Financials?November 9, 2023 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Call TranscriptDecember 7, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 8, 2023 | msn.comWhy Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?November 8, 2023 | finance.yahoo.comANI Pharmaceuticals Inc (ANIP) Reports Record Q3 2023 Results; Raises Full-Year GuidanceNovember 8, 2023 | finance.yahoo.comCompared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key MetricsNovember 8, 2023 | markets.businessinsider.comANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year OutlookNovember 8, 2023 | finance.yahoo.comANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 GuidanceNovember 6, 2023 | seekingalpha.com3 Catalysts Could Drive ANI Pharmaceuticals' PPS Growth Through November 2023November 2, 2023 | finance.yahoo.comPoseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?November 2, 2023 | investing.comANI Pharmaceuticals shares register monthly gain despite market volatilityNovember 2, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to NoteOctober 30, 2023 | finance.yahoo.comANI Pharmaceuticals to Participate at Two Upcoming Healthcare ConferencesOctober 25, 2023 | finance.yahoo.comANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ETOctober 20, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to KnowOctober 19, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Stock Moves -0.14%: What You Should KnowOctober 19, 2023 | markets.businessinsider.comExpert Ratings for ANI PharmaceuticalsOctober 13, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Stock Moves -0.48%: What You Should KnowOctober 6, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's WhyOctober 5, 2023 | finance.yahoo.com(ANIP) Advances While Market Declines: Some Information for InvestorsOctober 4, 2023 | seekingalpha.comANI Pharmaceuticals' officer sells $1.13M in company sharesSee More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year FoundedN/APrice Target and Rating Average Stock Price Target$71.67 High Stock Price Target$73.00 Low Stock Price Target$70.00 Potential Upside/Downside+47.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.52 Trailing P/E Ratio93.69 Forward P/E Ratio13.61 P/E GrowthN/ANet Income$-47,900,000.00 Net Margins2.98% Pretax Margin2.94% Return on Equity17.96% Return on Assets8.05% Debt Debt-to-Equity Ratio0.66 Current Ratio3.70 Quick Ratio2.91 Sales & Book Value Annual Sales$316.39 million Price / Sales3.15 Cash Flow$3.89 per share Price / Cash Flow12.52 Book Value$17.92 per share Price / Book2.72Miscellaneous Outstanding Shares20,440,000Free Float14,613,000Market Cap$995.84 million OptionableOptionable Beta0.88 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 45)President, CEO & Director Comp: $1.31MMr. Stephen P. Carey (Age 52)Senior VP of Finance & CFO Comp: $751kMr. James G. Marken (Age 60)Senior Vice President of Operations & Product Development Comp: $673.23kMr. Christopher K. Mutz (Age 51)Head of Rare Disease Comp: $565.17kMr. Ori Gutwerg (Age 49)Senior Vice President of Generics Comp: $623.89kMr. Muthusamy Shanmugam MS R.Ph. (Age 55)Head of R&D, COO of Novitium Operations & Director Ms. Meredith W. Cook (Age 49)Senior VP, General Counsel & Corporate Secretary Mr. Chad Gassert (Age 47)Senior Vice President of Corporate Development & Strategy Ms. Krista L. Davis (Age 50)Chief Human Resources Officer Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseMore ExecutivesKey CompetitorsAkero TherapeuticsNASDAQ:AKROLigand PharmaceuticalsNASDAQ:LGNDMorphoSysNASDAQ:MORMannKindNASDAQ:MNKDDay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 2,111 shares on 12/6/2023Ownership: 0.042%American Century Companies Inc.Bought 3,880 shares on 11/30/2023Ownership: 0.058%Deutsche Bank AGBought 2,570 shares on 11/24/2023Ownership: 0.037%Public Sector Pension Investment BoardSold 4,912 shares on 11/22/2023Ownership: 0.097%Graham Capital Management L.P.Bought 7,447 shares on 11/22/2023Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions ANIP Stock Analysis - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price target for 2024? 3 Wall Street research analysts have issued 1-year target prices for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $70.00 to $73.00. On average, they predict the company's stock price to reach $71.67 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2023? ANI Pharmaceuticals' stock was trading at $40.23 on January 1st, 2023. Since then, ANIP shares have increased by 21.1% and is now trading at $48.72. View the best growth stocks for 2023 here. Are investors shorting ANI Pharmaceuticals? ANI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 376,800 shares, a decline of 11.0% from the October 31st total of 423,400 shares. Based on an average daily trading volume, of 174,100 shares, the days-to-cover ratio is presently 2.2 days. View ANI Pharmaceuticals' Short Interest. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our ANIP earnings forecast. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.43. The specialty pharmaceutical company earned $131.83 million during the quarter, compared to the consensus estimate of $111.92 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.96% and a net margin of 2.98%. The company's revenue was up 57.3% compared to the same quarter last year. During the same period last year, the firm posted $0.46 EPS. What ETFs hold ANI Pharmaceuticals' stock? ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, October, 5th. The company provided EPS guidance of $3.62-$4.11 for the period, compared to the consensus estimate of $3.97. The company issued revenue guidance of $425.00 million-$445.00 million, compared to the consensus revenue estimate of $442.97 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Global Alpha Capital Management Ltd. (2.59%), William Blair Investment Management LLC (2.46%), Ranger Investment Management L.P. (2.10%), Invesco Ltd. (1.67%), AIGH Capital Management LLC (1.34%) and Ameriprise Financial Inc. (1.22%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ANIP) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.